Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins

Paul G. McNally, Nigel I. Jowett, Jenny J. Kurinczuk, Richard W. Peck and John R. Hearnshaw

The Leicester Royal Infirmary, Leicester LE1 5WW, UK.

Summary: Lipatrophy and lipohypertrophy were the most frequently reported local complications of conventional insulin therapy. Early reports following the introduction of highly purified insulins suggested a reduction in the frequency of lipohypertrophy and lipoatrophy. Since highly purified insulins have been in common usage for 10 years, the present frequency of these complications was assessed in a study of 281 insulin treated diabetics. Lipohypertrophy was recorded in 76 (27.1%) patients including 3 with associated lipoatrophy. Lipoatrophy was found in 7 (2.5%) cases (3 porcine and 4 bovine insulin treated), 4 of which had only ever used highly purified insulins. Despite the introduction of highly purified insulins, lipohypertrophy and lipoatrophy remain prevalent in insulin treated patients. This common complication may be limited by routinely inspecting injection sites.

Introduction

Lipohypertrophy and lipoatrophy were the most frequently reported local complications of insulin therapy in patients treated with conventional unpurified insulins.1-2 Lipoatrophy is most commonly seen in children and women soon after the initiation of insulin treatment, and is characterized by loss of subcutaneous fat at the site of injection. In contrast, lipohypertrophy is marked by prominent fatty swellings at the site of repeated injections.

Early reports following the introduction of the highly purified insulins found a reduction in the incidence of lipoatrophy, although the frequency of lipohypertrophy remained unchanged.3-4 Nevertheless sporadic cases of lipoatrophy have been reported with both highly purified bovine and porcine insulins.5-6

Since highly purified insulins have now been in common use for 10 years, we have examined the injection sites of our insulin treated patients for evidence of lipohypertrophy and lipoatrophy to establish the present frequency of these potentially avoidable complications.

Methods

The injection sites of 281 (151 M:130 F) consecutive insulin treated diabetics attending a diabetic clinic over a 3 month period were examined (by PGM and NIJ) for abnormalities. These were classified as lipoatrophy (sharply defined disappearance of subcutaneous fat without inflammation), lipohypertrophy (visible and palpable fatty swellings) and superficial fibrotic nodules (small raised lesions related to the intradermal injection of insulin). All patients had used highly purified insulins for 6 months or longer. Details of the types of insulin in use, as well as those in the past were obtained from the patient and verified by the medical records. Patients were asked if they regularly rotated their injection sites, and if they were aware of the local complications of insulin therapy. A glycosylated haemoglobin was performed to assess recent glycaemic control.

Results

Insulin-induced lipohypertrophy or lipoatrophy was recorded in 80 patients (28.5%), with no difference in the incidence between sexes (42 M:38 F). Fifty-five of these patients were currently using purified porcine insulins, 22 patients purified bovine insulins and 3 patients human insulins. The mean duration of treatment using highly purified insulins was 5.5 years (range 0.5–9 years). Fifty-two patients (65%) had previously used unpurified insulins, with 21 (40%) of this group developing lipohypertrophy (18

Correspondence: P.G. McNally B.M., M.R.C.P., Renal Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK.
Accepted: 5 July 1988

© The Fellowship of Postgraduate Medicine, 1988
cases) or lipoatrophy (3 cases) when injecting these insulins.

Seven cases of lipoatrophy were recorded, with 3 patients using highly purified porcine insulins, and 4 cases following purified bovine insulins. In 3 cases lipoatrophy had complicated unpurified insulin therapy, but the other 4 cases had only ever used purified insulins. Lipohypertrophy was recorded in 76 patients, including 3 with associated lipoatrophy (Table I). The preparation of insulin used is shown in Table II. Superficial fibrotic nodules were seen in 9 patients.

### Table I Clinical details of patients studied (n=281)

<table>
<thead>
<tr>
<th></th>
<th>Lipoatrophy</th>
<th>Lipo-hypertrophy</th>
<th>Normal sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (%)</td>
<td>7 (2.5)</td>
<td>76 (27.1)</td>
<td>201 (70.4)</td>
</tr>
<tr>
<td>Sex (M:F)</td>
<td>3:4</td>
<td>40:36</td>
<td>111:90</td>
</tr>
<tr>
<td>Mean age in years (age range)</td>
<td>61.6 (40-76)</td>
<td>40 (11-82)</td>
<td>46.3 (7-86)</td>
</tr>
<tr>
<td>Mean duration of insulin treatment in years (s.d.)</td>
<td>11.6 (10.0)</td>
<td>14.3 (9.8)</td>
<td>9.4 (9.7)</td>
</tr>
<tr>
<td>Number without regular injection rotation (%)</td>
<td>4 (57.1)</td>
<td>46 (60.5)</td>
<td>112 (55.7)</td>
</tr>
<tr>
<td>Number with knowledge of local complications at injection sites (%)</td>
<td>4 (57.1)</td>
<td>43 (56.6)</td>
<td>117 (58.2)</td>
</tr>
<tr>
<td>Mean glycosylated haemoglobin % (s.d.)</td>
<td>8.5 (2.2)</td>
<td>9.5 (2.6)</td>
<td>9.2 (2.4)</td>
</tr>
<tr>
<td>Never used unpurified insulins (%)</td>
<td>4 (57.1)</td>
<td>24 (31.6)</td>
<td>109 (54.2)</td>
</tr>
</tbody>
</table>

### Table II Preparation of insulin injected

<table>
<thead>
<tr>
<th>Insulin preparation injected</th>
<th>Number (%) of patients with:</th>
<th>Lipoatrophy</th>
<th>Lipo-hypertrophy</th>
<th>Normal sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soluble insulin alone</td>
<td></td>
<td>5 (42%)</td>
<td>7 (58%)</td>
<td></td>
</tr>
<tr>
<td>Isophane insulin</td>
<td>1 (0.5%)</td>
<td>62 (26%)</td>
<td>172 (73.5%)</td>
<td></td>
</tr>
<tr>
<td>Insulin zinc suspension</td>
<td>6 (18%)</td>
<td>6 (18%)</td>
<td>22 (64%)</td>
<td></td>
</tr>
</tbody>
</table>

### Injection routine

Forty-eight of the patients (60%) with lipohypertrophy or lipoatrophy had no regular routine for rotating their injection sites, and only 59.0% were aware that repeated injection into a limited area could lead to local complications. No difference in injection practice or knowledge concerning local complications following insulin therapy was seen in those with normal injection sites. Table III shows details of the injection practice of the patients studied.

### Glycaemic control

The mean glycosylated haemoglobin of patients with abnormal injection sites was 9.55% (s.d. 2.62, normal range 4-8.5%) which did not differ significantly from the patients with normal injection sites (9.22%, s.d. 2.4; Mann–Whitney U-test, P=0.24).

### Discussion

Lipohypertrophy and lipoatrophy remain a frequent complication of insulin therapy in diabetic patients, despite the introduction and common usage of highly purified insulins. One third of the patients studied had evidence of either lipoatrophy or lipohypertrophy at their regular injection sites. The incidence of lipohypertrophy (27.1%) is similar in frequency to that found by other workers. Most patients with lipohypertrophy admitted to restricting their injections to anatomically small regions, as the fatty swellings were convenient areas.

### Table III Injection practice of patients studied

<table>
<thead>
<tr>
<th></th>
<th>Lipoatrophy</th>
<th>Lipo-hypertrophy</th>
<th>Normal sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection site used regularly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arm</td>
<td>5 (71%)</td>
<td>26 (34%)</td>
<td>63 (31%)</td>
</tr>
<tr>
<td>Leg</td>
<td>7 (100%)</td>
<td>67 (88%)</td>
<td>171 (85%)</td>
</tr>
<tr>
<td>Abdomen</td>
<td>2 (29%)</td>
<td>20 (26%)</td>
<td>85 (42%)</td>
</tr>
<tr>
<td>Buttocks</td>
<td>1 (14%)</td>
<td>14 (18%)</td>
<td>24 (12%)</td>
</tr>
<tr>
<td>Number using one anatomical region only (e.g. legs)</td>
<td>1 (14.3%)</td>
<td>40 (52.6%)</td>
<td>100 (49.8%)</td>
</tr>
<tr>
<td>Number using two anatomical regions</td>
<td>4 (57.1%)</td>
<td>25 (32.9%)</td>
<td>63 (31.3%)</td>
</tr>
<tr>
<td>Number using three or more anatomical regions</td>
<td>2 (28.6%)</td>
<td>11 (14.5%)</td>
<td>36 (17.9%)</td>
</tr>
</tbody>
</table>
to aim for, and were less painful for injection (Figure 1). The prevalence of lipoatrophy (2.5%) recorded in our patients on purified insulin therapy has not been reported before. No cases of lipoatrophy were reported by either Wright et al.2 or Young et al.3 in patients treated with purified porcine insulins. Although sporadic cases of lipoatrophy have appeared in the literature in patients using both purified bovine and porcine insulins, the results of our survey suggest that lipoatrophy may still be a clinical problem (Figure 2). Previous studies identified young female patients as the high risk group for developing lipoatrophy,1 but no such association was seen in this survey, where the average age was much older and occurred with a similar frequency in both sexes.

Although patients are frequently advised to rotate their injection sites to prevent or limit the development of lipohypertrophy or lipoatrophy, true rotation using more than one anatomical site was seen in only 50% of those studied. No increase in the frequency of local complications was seen however in those patients who restricted their injections to one anatomical site, which suggests that if rotation takes place within one anatomical area then lipohypertrophy or lipoatrophy will not necessarily result.8 Indeed an improvement in metabolic control may ensue in some patients if they restrict themselves to one region only, since the absorption of insulin may vary considerably between anatomical sites.9

The development of superficial fibrotic nodules reflects faulty injection technique, which therefore needs to be reviewed. These lesions may not only be painful but can lead to poor diabetic control, following leakage of insulin onto the surface of the skin.

The pathogenesis of lipoatrophy is not clearly established although Reeves et al.10 suggested a local immune reaction following the demonstration of immune complexes, complement fixation and inflammatory mediators at the site of atrophy. Furthermore the presence of zinc or fish protamine in modified insulins may provide a readily available source of antigen and enhance the immunological reaction to insulin.11 The majority of patients with lipoatrophy in this study (85%) were using a zinc based preparation. In contrast, lipohypertrophy is regarded as due to a local anabolic effect of insulin promoting fat and protein synthesis.12 It is probable that the constant injection of insulin into the same area is the important factor in producing hypertrophy rather than the actual dose of insulin injected.13

Absorption of insulin from areas of lipohypertrophy or lipoatrophy (especially lipohypertrophy) is variable due to the formation of fibrous scar tissue at the injection site, and may lead to poor

Figure 1 Lipohypertrophy complicating treatment with highly purified porcine insulin.

Figure 2 Lipoatrophy complicating highly purified porcine insulin.
Clinical or overt hyperglycaemia and hypo-
glycaemia, which might explain why no significant
absorption may manifest as periods of sub-
glycaemic control, areas may delay
control. However, wide
swings in blood glucose levels are clearly
undesirable.

Local complications following highly purified
bovine or porcine insulins are still common in
insulin treated diabetics. Poor injection sites are not
only unsightly, but may also lead to poor glycaemic
control. Highly purified insulins provide no
guarantee against lipohypertrophy and lipoatrophy,
which may be limited by routinely inspecting
injection sites at clinic visits.

References

1. Renold, A.E., Winograd, A.I. & Martin, D.B. Diabe-
sue et tissue adipeux. Helv Med Acta 1957, 24:
322–327.

Malins, J.M. Very pure porcine insulin in clinical

3. Teuscher, A. Treatment of insulin lipoatrophy with
monocomponent insulin. Diabetologia 1974, 10:
211–214.

4. Young, R.J., Steel, J.M., Frier, B.M. & Duncan,
L.J.P. Insulin injection sites in diabetes – a neglected

5. Evans-Jones, L.G. Lipoatrophy in a patient on highly
purified beef insulin. Arch Dis Child 1982, 57:
638–639.

& Hayes, T.M. Lipoatrophy and monocomponent

7. Jowett, N.I. & McNally, P.G. Lipoatrophy with
highly purified insulins and treatment with
recombinant human insulin. Practical Diabetes 1988,
5: 130–131.

injection technique and diabetic control. Practical
Diabetes 1984, 1: 10–12.

absorption and in blood glucose control associated
with varying insulin injection sites in diabetic patients.

10. Reeves, W.G., Allen, B.R. & Tattersall, R.B. Insulin-
induced lipoatrophy: evidence for an immune patho-

11. Reeves, W.G. Immunology of diabetes and insulin
therapy. In: Thomson, R.A. (ed) Recent Advances in
Clinical Immunology. Churchill Livingstone, Edin-

12. Renold, A.E., Marble, A. & Fawcett, D.W. Action of
insulin on deposition of glycogen and storage of fat in

abdominal lipohypertrophy after continuous sub-
1539.

14. Bressler, R. & Galloway, J.A. Insulin treatment of
860–876.

15. Young, R.J., Hannan, W.J., Frier, B.M., Steel, J.M.
& Duncan, L.J.P. Diabetic lipohypertrophy delays
Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins.


*Postgrad Med J* 1988 64: 850-853
doi: 10.1136/pgmj.64.757.850

Updated information and services can be found at:
http://pmj.bmj.com/content/64/757/850

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/